STRIDES PHARMA INTL
GenericsSTRIDES PHARMA INTL is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Metabolic. Key products include LYVISPAH.
STRIDES PHARMA INTL's Key Drugs
STRIDES PHARMA INTL's core commercial portfolio centers on SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
STRIDES PHARMA INTL's Recent FDA Approvals
New NDA/BLA approvals for STRIDES PHARMA INTL over the last two years — novel drugs only, excluding generics and label supplements.
STRIDES PHARMA INTL's Therapeutic Areas
STRIDES PHARMA INTL's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
STRIDES PHARMA INTL's Top Competitors
STRIDES PHARMA INTL's closest competitors by therapeutic-area and drug-target overlap include Merck, GSK, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
STRIDES PHARMA INTL Pipeline Snapshot
Active clinical trials for STRIDES PHARMA INTL across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (3)
Company Info
- First Approval
- 1953-12-07
- Latest
- 2026-06-18
- Applications
- 110